LTZ Therapeutics Closes $38M Funding Round

Deal Summary

Redwood City‑based LTZ Therapeutics, a clinical‑stage immunotherapy biotech, announced the completion of an oversubscribed $38 million financing round. The funding will support the company's development of next‑generation immunotherapy treatments.